CapsoVision

CV · NASDAQ

$6.68+$0.01 (+0.15%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $6.67

CV analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 5 analysts

Average $9.69 (+45.1% upside)

Low: $9.09
Now: $6.68
High: $10.50

Upgrades and downgrades

The latest rating actions, newest first

CV analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Benchmark	Mar 27, 2026	Maintains	Speculative Buy	$14.00 → $10.00	32%
Benchmark	Dec 31, 2025	Maintains	Speculative Buy	$5.00 → $14.00	32%

The case for and against

Updated Jan 12, 2026

Bull case

CapsoVision Inc. has successfully utilized its CapsoCam Plus technology in over 135,000 procedures, contributing nearly $12 million in revenue for 2024, which signifies robust market acceptance and share gains. The company has demonstrated consistent revenue growth every year since entering the U.S. market, highlighting its strong operational momentum. Additionally, the ongoing development of the CapsoColon 3D, aimed at large intestine imaging, positions the company favorably for future revenue expansion in the gastrointestinal imaging market.

Bear case

CapsoVision Inc faces significant challenges that could impede its financial growth and overall profitability. Resistance from key stakeholders, including physicians and hospitals, particularly related to the retrieval process of the ingestible capsule, is expected to hinder revenue expansion. Furthermore, potential manufacturing disruptions, adverse clinical outcomes, or product recalls, alongside regulatory limitations on product sales in new markets, raise concerns about investor confidence and long-term financial performance.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.